As NExT demonstrated exceptional intratumor accumulation and remarkable therapeutic efficacy in PDL1+ TNBC cells, we conducted further investigations into the therapeutic potential of autologous patient-derived NExT in a PDL1+ tumor-in-mouse model derived from a TNBC patient (UGR01). This evidence concerns the gene CD274 and neoplasm.